



Catalog Number:	MC11055	Product Type:	Small Molecule
Bio-Activity:	ATM Kinase inhibitor	CAS #:	587871-26-9
Research Categories:	Neuroscience, cancer	Chemical Name:	2-(4-Morpholinyl)-6-(1-thiamthrenyl)-4H-pyran-4-one
Solubility:	Soluble in DMSO (up to 40 mg/ml) or in Ethanol (up to 20 mg/ml).	Molecular Formula:	C21H17NO3S2
Purity:	> 98%	Molecular Weight:	395.50
Format:	Powder	Ship Temp:	Ambient
Storage:	Room Temperature		

Application Notes

Description/Data:

Potent and selective ATM kinase inhibitor IC₅₀s= 13, 2500, 9300, 16600, >100000 and >100000 nM for ATM, DNA-PK, mTOR, PI 3-kinase, PI 4-K and ATR respectively [1]. Decreases viability of MCF-7, A549 and HCT116 cells and decreases p21CIP1 levels in vitro [2]. Disruption of ATM signaling in primary A-T fibroblasts leads to dysregulation of ribonucleotide reductase and increase resistance to inhibitors of mitochondrial respiration and translation [3]. Sensitizes radio-resistant cancer cells [4]. Provides neuroprotection against H₂O₂-induced cell damage [5].

References:

- 1) Hickson et al. (2004), Identification and characterization of a novel and specific inhibitor of the ataxia-telangiectasia mutated kinase ATM; Cancer Res., 64 9152
- 2) Crescenzi et al. (2008), Ataxia telangiectasia mutated and p21CIP1 modulate cell survival of drug-induced senescent tumor cells: implications for chemotherapy; Clin. Cancer Res. 14 1877
- 3) Eaton et al. (2007), Ataxia-telangiectasia mutated kinase regulates ribonucleotide reductase and mitochondrial homeostasis; J. Clin. Invest., 117 2723
- 4) T Zhang et al. (2015) The ATM inhibitor KU55933 sensitizes radioresistant bladder cancer cells with DAB2IP gene defect; Int. J. Radiat. Biol., 91:368

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

5) J Chwastek et al. (2017) The ATM kinase inhibitor KU-55933 provides neuroprotection against hydrogen peroxide-induced cell damage via a γ H2AX/p-p53/caspase-3-independent mechanism: Inhibition of calpain and cathepsin D; Int. J. Biochem. Cell Biol. 87:38

FOR RESEARCH USE ONLY

NEUROMICS' REAGENTS ARE FOR IN VITRO AND CERTAIN NON-HUMAN IN VIVO EXPERIMENTAL USE ONLY AND NOT INTENDED FOR USE IN ANY HUMAN CLINICAL INVESTIGATION, DIAGNOSIS, PROGNOSIS, OR TREATMENT. THE ABOVE ANALYSES ARE MERELY TYPICAL GUIDES. THEY ARE NOT TO BE CONSTRUED AS BEING SPECIFICATIONS. ALL OF THE ABOVE INFORMATION IS, TO THE BEST OF OUR KNOWLEDGE, TRUE AND ACCURATE. HOWEVER, SINCE THE CONDITIONS OF USE ARE BEYOND OUR CONTROL, ALL RECOMMENDATIONS OR SUGGESTIONS ARE MADE WITHOUT GUARANTEE, EXPRESS OR IMPLIED, ON OUR PART. WE DISCLAIM ALL LIABILITY IN CONNECTION WITH THE USE OF THE INFORMATION CONTAINED HEREIN OR OTHERWISE, AND ALL SUCH RISKS ARE ASSUMED BY THE USER. WE FURTHER EXPRESSLY DISCLAIM ALL WARRANTIES OF MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE.-V2/08/2012

www.neuromics.com

Neuromics Antibodies • 5325 West 74th Street, Suite 8 • Edina, MN 55439
phone 866-350-1500 • fax 612-677-3976 • e-mail: pshuster@neuromics.com